Reneuron Share Discussion Threads

[esmerelda] 07/4/2016 20:32

Sincere thanks RF for posting the link and to twodegrees for the text as I hadn't seen that.

Edison Investments are projecting a 2016 expenditure of £7.6m per half year and a 2017 expenditure of £13.8m per half year (or at least that's what their EBITA figures suggest). Now that isn't £2m per month for 2016 but it certainly is for 2017. In mitigation I suggest the 2017 numbers are only likely IF the 2016 test results suggest a positive outcome (otherwise that particular test and its future expenditure would be shut down). Those figures also suggest that the company has sufficient funds to last into 2018 without a further cash call which is what the interviews with the CFO had suggested.

That leaves me comfortable with me investment whilst appreciating that I am effectively gambling on a successful outcome. On more positive news I would look to add more, otherwise I'll be out of here. (That, I believe, is stating the obvious for all investors!)

[twodegrees] 07/4/2016 20:03

Executive Interview - ReNeuron

ReNeuron is a UK biotech company developing allogeneic (off-the-shelf) novel stem cell therapies to address debilitating conditions with significant unmet clinical needs. Neural stem cell-based products, developed from an immortalised CTX single cell line, are in clinical studies: ReN001 in Phase II aimed at improving disability in ischaemic stroke patients and ReN009 in Phase I for critical limb ischaemia. ReN003, derived from human retinal progenitor cells, will enter a Phase I/II study for retinitis pigmentosa by H215.

CFO Michael Hunt outlines the company’s cell-based technology platforms and highlights the potential clinical data catalysts that investors should watch out for over the next 12-18 months. He also comments on the company’s solid financial position, which enables the development of its multiple products to their next valuation inflection points, with Neil Woodford of Woodford Investment Management now a cornerstone investor (19.9% stake).

[twodegrees] 07/4/2016 19:58

Is ReNeuron Group Plc a Sell? The Stock Declines Again
by Linda Rogers — April 7, 2016




The stock of ReNeuron Group Plc (LON:RENE) is a huge mover today! The stock is up 1.63% or GBX 0.05 after the news, hitting GBX 3.05 per share. About 81,082 shares traded hands. ReNeuron Group Plc (LON:RENE) has declined 42.86% since September 3, 2015 and is downtrending. It has underperformed by 47.65% the S&P500. The move comes after 7 months negative chart setup for the GBX 95.88M company. It was reported on Apr, 7 by Barchart.com. We have GBX 2.65 PT which if reached, will make LON:RENE worth GBX 12.46M less.



ReNeuron Group Plc , based in the United Kingdom, is engaged in clinical-stage stem cell company. The company has a market cap of 95.88 million GBP. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It currently has negative earnings. It develops cell therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments.




ReNeuron Group Plc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’;s FREE daily email newsletter

[esmerelda] 07/4/2016 18:23

I have done research but can't find any published evidence to support your claims and that is why I politely ask you to point me that direction. I have read all the documents on their website, listened to the podcasts, researched the company on the Internet, etc but a doubling in monthly expenditure is not mentioned or even hinted at anywhere I have looked. You can be as patronising as you like towards me but I need your assistance to find that information in the public environment and your assistance is appreciated.

[rocket fuel] 07/4/2016 17:25

Es, do your research, go find it. You should know that info if you are a shareholder.

[esmerelda] 07/4/2016 17:16

RF Can you please show or point me to where you get the figure of £2m a month from? The accounts published last December suggest it is running at £1m per month and they are fully funded through to 2018.I can accept your view that it would be sub-2p after the release of (negative) results. (I believe you missed the negative word out as it is unlikely that the price would fall that far on the back of a positive outcome).

[rocket fuel] 07/4/2016 14:07

Some of the new holders here need to do a bit more research, in fact a lot more research. Rene are currently burning more than £2m per month

[rocket fuel] 07/4/2016 14:04

I have never lost a penny on this blag nor on rene mark1 when they fleeced Her Maj the Queen out of a small fortune at £2 a pop.

As for shooting the company down, they will do that themselves to get the company on the brink of admin before a deal is done with city friends to delist and move the co into private hands without a penny returned to the beloved shareholders. All legal and above board of course.

[stewart_25] 07/4/2016 13:35

RF shooting it down again.... wanting to get back in and recoup your losses RF?

[rocket fuel] 07/4/2016 12:45

sub 2p here after release of results and ultimately no shareholder value here at all for the AIM punters.

[city chappy] 07/4/2016 12:38

That's why they had the Placing.

"In the Company's July preliminary results statement, we reported substantial progress across all of our therapeutic programmes. We also announced a GBP68.4 million placing, the proceeds from which have now been received. This major financing provides the funding to enable us to take all of our current therapeutic programmes into clinical development and, subject to future clinical data and regulatory approvals, to enable us to take our therapeutic programmes in stroke and retinitis pigmentosa through late-stage clinical development to the point of first application for market authorisation."

[rocket fuel] 07/4/2016 11:51

Total cash burn this financial yr will be c£16m and c£28m next yr

[small crow] 07/4/2016 11:45

Exosomes

hxxp://www.the-scientist.com/?articles.view/articleNo/45577/title/Cancer-s-Vanguard/&utm_campaign=NEWSLETTER_TS_The-Scientist-Daily_2016&utm_source=hs_email&utm_medium=email&utm_content=28059011&_hsenc=p2ANqtz-8rKRwUx-SffFe3qJqJn2XS0QFYa16pYVSTUO2enp5EL-rFjum-BQAb4U6Z6QjnyZ3wI23ZTcSpLRZONfSHHuFrC1cjiA&_hsmi=28059012

[noteworthy5] 07/4/2016 11:23

They are currently spending less than £1m per month but this will increase (loss for the 2nd half of last year was £4.48 million, with cash outflow from operations of £5.26 million).

They raised £68.4 million in a Placing last August and the Interim results in December said they had cash, cash equivalents and bank deposits at 30/9/2015 of £72.28 million. On 11/1/2016 they were awarded a further £2.1 million grant from Innovate UK to advance the exosomes in cancer. They recently stated they have cash to last until end 2018.

They expect to be able to submit marketing applications for the lead stroke treatment and retinitis pigmentosa (which is on the FDA's fast track route) in 2018, which is within the current cash window and by when they will also have Phase 1 results on the cancer treatment. The likely scenario is a takeover 2018.

This has mega bagger written all over it.

[rocket fuel] 07/4/2016 10:14

More than £2m per month burning bright in the rene furnace at present with another five years at least before any product seeks FDA approval, and after raising c£170m from the mug punter AIM speculators since their second bite of the ipo cherry rene will no longer be able to milk the dairy around here and will go into private hands with no return to shareholders.

[stewart_25] 07/4/2016 09:11

very confident speaker - impressed with him. Now just for some results and share price move...

[noteworthy5] 06/4/2016 20:31

Rene's CEO speaks last week.

[noteworthy5] 05/4/2016 12:30

SAR up 58% today, and a 5 fold increase since mid February, on regulatory approval announced today to commence Phase 1 trials with its drug for pancreatic and lung cancer.

[city chappy] 04/4/2016 15:07

Dendreon's share price soared from $0.3 billion in Feb 2009 to $7.3 billion in Apr 2010 on approval of its prostate cancer drug Provenge.

Reneuron have a cancer treatment based on its exosome platform which in preclinical tests has repeatedly produced complete tumour collapse within three weeks of administration. It enters Phase 1 human trial next year. Any continued indication of success in treating cancer and Rene's shares will soar, with or without positive news from their other potentially transformational stroke and retinitis pigmentosa treatments.

Rene have first mover advantage in the field of exosomes. If they target something like brain tumours, which are expensive and risky to treat surgically, they could be onto a winner.

Starting to build a stake in Rene myself. The spread across three or four main areas (stroke, RP and cancer) spreads the risk and their strong cash balance means they could be self-funding until the likely target exit of a company take-over. This has the makings of a 50 bagger.

[dickbush] 04/4/2016 12:11

Woodford isn't immune to making mistakes with small cap drug research companies.

[noteworthy5] 04/4/2016 10:13

Some background to fund manager Neil Woodford recently taking a 20% stake in Reneuron. For him to choose to invest in a small cap is unusual and shows the confidence he has in the company.

www.telegraph.co.uk/finance/personalfinance/investing/funds/10952350/Will-Neil-Woodford-launch-a-smaller-companies-fund.html

[noteworthy5] 31/3/2016 10:22

The Phase I stem cell stroke trial recruitment has ended and I understand they are now gathering and analysing data. This could be transformational for stroke treatment and Reneuron. That man in the youtube video definately attributed his improvement to the Reneuron treatment.

[city chappy] 23/3/2016 19:51

Thanks ElGordo. I remember seeing the BBC article and encouraging youtube video on the Rene stroke trial participiant three years ago and thinking they might be worth coming back to once they had progressed. Key inflection points and value adding factors now:-

- Stroke Phase I data due Q2 2016 (Phase II planned to commence in H2 2016).
- Stroke mobility Phase II due mid 2016 (pivotal Phase II/III planned to commence in 2017).
- Retinitus pigmentosa commenced Phase I/II Mar 2016 (pivotal Phase II/III planned to commence in 2017, with 'fast track' to market in 2018).
- Exosome planned to commence Phase I/II in 2017. Panning out to include cancer with amazing preclinical results (tumour collapse) within 3 weeks of treatment and independent grant support.
- Fully funded to bring at least two products to marketing applications in 2018 and continue progressing the whole pipeline.
- Neil Woodford taking a large shareholding late last year.

---------------------


ElGordo
23 Mar'16 - 11:59 - 4770 of 4771 1 0



Or the original BBC page

[stewart_25] 23/3/2016 15:49

i didn't realise that much improvement had taken place from the original safety trials - how has the share price not moved upon that video evidence alone?